<DOC>
	<DOC>NCT01549106</DOC>
	<brief_summary>The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of IPI-145 after single and repeat oral administration, and to evaluate the effects of food and ketoconazole on the plasma pharmacokinetics of IPI-145.</brief_summary>
	<brief_title>IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction Study</brief_title>
	<detailed_description />
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>1. Gender : male or female 2. Age : 1855 years, inclusive 3. Body Mass Index (BMI) : 18.030.0 kg/m2 4. Medical history without major pathology 5. For males only: Willingness to use adequate contraception from the time of dosing and not donate sperm until 3 months after the followup visit 6. Females who have a negative pregnancy test at screening and on each admission, and are of nonchildbearing potential. Females of nonchildbearing potential are defined as women who are surgically sterile or postmenopausal (defined as at least 1 year post cessation of menses and follicular stimulating hormone (FSH) &gt;23.0 mIU/mL) 7. Willing and able to sign the written Informed Consent Form (ICF) 1. Previous participation in the current study 2. Evidence of clinically relevant pathology 3. History of relevant drug and/or food allergies 4. Part 4 only: Known or suspected adverse reaction or contraindication to the imidazole class of drugs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>